Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$35.51 USD
+0.41 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $35.50 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Supernus Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Generic Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SUPN 35.51 +0.41(1.15%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for SUPN
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics | SUPN Stock News
Supernus completes acquisition of Sage Therapeutics
Biogen rises as Alzheimer’s therapy drives Q2 beat
Supernus (SUPN) Receives Upgrade and Increased Price Target
Supernus (SUPN) Receives Upgrade from Cantor Fitzgerald